Shore Capital reaffirmed their hold rating on shares of AstraZeneca (LON:AZN) in a research report released on Wednesday.

A number of other research firms also recently issued reports on AZN. JPMorgan Chase & Co. restated a buy rating on shares of AstraZeneca in a report on Wednesday, June 6th. Goldman Sachs Group set a GBX 3,750 ($47.84) price objective on shares of AstraZeneca and gave the stock a sell rating in a report on Wednesday, May 30th. Deutsche Bank restated a buy rating and set a GBX 6,000 ($76.54) price objective on shares of AstraZeneca in a report on Friday, July 27th. Credit Suisse Group restated an outperform rating and set a GBX 5,900 ($75.26) price objective on shares of AstraZeneca in a report on Tuesday, June 12th. Finally, Morgan Stanley set a GBX 5,250 ($66.97) target price on shares of AstraZeneca and gave the stock a neutral rating in a research note on Tuesday, May 22nd. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of GBX 5,605.09 ($71.50).

LON AZN opened at GBX 5,930 ($75.65) on Wednesday. AstraZeneca has a 52-week low of GBX 4,260 ($54.34) and a 52-week high of GBX 5,520 ($70.42).

The firm also recently announced a dividend, which will be paid on Monday, September 10th. Stockholders of record on Thursday, August 9th will be paid a GBX 68.40 ($0.87) dividend. The ex-dividend date is Thursday, August 9th. This represents a dividend yield of 1.19%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Google Finance

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.